Hier finden Sie grundlegende Angaben zu klinischen Studien des Comprehensice Cancer Centers Mainfranken (CCC MF)
Filter aktiv
Seite 3 - Studien 21 bis 30 von insgesamt 38
- Rekrutierung läuftDAREON-9: A Phase Ib open-label dose escalation and dose confirmation safety study of intravenous BI 764532 in combination with topotecan for the treatment of patients withsmall cell lung cancerBI-1438-0009Molekulare Marker
- Rekrutierung läuftEine offene, forschungsinitiierte Phase I/II – Studie mit Venetoclax in Kombination mit Blinatumomab Immuntherapie bei erwachsenen Patienten mit rezidivierter/refraktärer ALLMolekulare Marker
- Rekrutierung läuftIndividualized Therapy for Relapsed Malignancies in Childhood
- Rekrutierung läuftInternational Study for Treatment of High Risk Childhood Relapsed ALL 2010
- Rekrutierung läuftA Phase III, Randomized, Open-Label, Multicenter Study Evaluating the Efficacy and Safety of Divarasib Versus Sotorasib or Adagrasib in Patients With Previously Treated KRAS G12C-Positive Advanced or Metastatic Non-Small Cell Lung Cancer
- Rekrutierung läuftA Phase 3 Randomized, Open-Label, Multicenter Study Evaluating the Efficacy of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Subjects with Relapsed/Refractory Follicular Lymphoma
- Rekrutierung läuft
A Phase 3 Open-Label, Randomized Study of Fixed Duration Pirtobrutinib (LOXO-305) plus Venetoclax and Rituximab versus Venetoclax and Rituximab in Previously Treated Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma (BRUIN CLL-322)
- Rekrutierung läuftNon-Hodgkin Lymphoma: Epcoritamab in Combination with Anti-Neoplastic AgentsMolekulare Marker
- Rekrutierung läuftA Dose Escalation and Expansion Study of ABBV-383 in Combination with Anti-Cancer Regimens for the Treatment of Patients with Relapsed/Refractory Multiple Myeloma
- Rekrutierung läuftA phase 3 open-label, randomized, controlled study to evaluate the efficacy and safety of petosemtamab compared with investigator’s choice monotherapy treatment in previously treated patients with incurable, metastatic/recurrent head and neck squamous cell carcinomaIndikationen